A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

Summary

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in ccRCC.

Timeline

Start

2023-09-25

Primary completion

2024-09-25

Completion

2025-09-25

Drugs

Indications